|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ELN 6-K filed Dec 15, 2009. About Transition
Transition
is a biopharmaceutical company, developing novel therapeutics for disease
indications with large markets. Transition's lead products include ELND005 for
the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes.
Transition has an emerging pipeline of preclinical drug candidates acquired
externally and developed internally using its proprietary drug discovery engine.
Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the
Toronto Stock Exchange under the symbol "TTH". For additional information about
the Company, please visit www.transitiontherapeutics.com.
-2-
|
| |||||||